Pfizer's first-quarter revenues slid by almost $1.5 billion, or 9%, to $13.5 billion, compared to the same period last year. During an earnings call Tuesday, the company attributed part of the decline to continued generics-induced erosion, including cholesterol ...
[Published Medical Marketing And Media - Apr 30 2013]